AnaptysBio, Inc. (ANAB)
55.64
-1.64
(-2.87%)
USD |
NASDAQ |
Aug 28, 15:21
AnaptysBio Price to Book Value : 126.73 for Aug. 28, 2026
Price to Book Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Price to Book Value Data
| Date | Value |
|---|---|
| August 27, 2026 | 130.47 |
| August 26, 2026 | 132.09 |
| August 25, 2026 | 132.93 |
| August 24, 2026 | 133.09 |
| August 21, 2026 | 131.50 |
| August 20, 2026 | 129.11 |
| August 19, 2026 | 134.96 |
| August 18, 2026 | 134.35 |
| August 17, 2026 | 135.94 |
| August 14, 2026 | 133.16 |
| August 13, 2026 | 127.58 |
| August 12, 2026 | 129.77 |
| August 11, 2026 | 131.80 |
| August 10, 2026 | 126.33 |
| August 07, 2026 | 128.93 |
| August 06, 2026 | 124.74 |
| August 05, 2026 | 125.24 |
| August 04, 2026 | 125.56 |
| August 03, 2026 | 122.21 |
| July 31, 2026 | 121.52 |
| July 30, 2026 | 125.35 |
| July 29, 2026 | 118.75 |
| July 28, 2026 | 118.68 |
| July 27, 2026 | 122.09 |
| July 24, 2026 | 123.32 |
| Date | Value |
|---|---|
| July 23, 2026 | 125.05 |
| July 22, 2026 | 119.82 |
| July 21, 2026 | 122.44 |
| July 20, 2026 | 114.53 |
| July 17, 2026 | 132.09 |
| July 16, 2026 | 123.32 |
| July 15, 2026 | 127.13 |
| July 14, 2026 | 142.36 |
| July 13, 2026 | 158.99 |
| July 10, 2026 | 151.20 |
| July 09, 2026 | 151.66 |
| July 08, 2026 | 148.83 |
| July 07, 2026 | 153.33 |
| July 06, 2026 | 141.91 |
| July 02, 2026 | 144.44 |
| July 01, 2026 | 149.01 |
| June 30, 2026 | 153.73 |
| June 29, 2026 | 150.24 |
| June 26, 2026 | 143.82 |
| June 25, 2026 | 135.92 |
| June 24, 2026 | 133.18 |
| June 23, 2026 | 135.35 |
| June 22, 2026 | 136.62 |
| June 18, 2026 | 130.98 |
| June 17, 2026 | 129.29 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| 4D Molecular Therapeutics, Inc. | 1.949 |
| Design Therapeutics, Inc. | 4.715 |
| Inhibrx Biosciences, Inc. | -- |
| Agenus, Inc. | -- |
| Amgen, Inc. | 19.96 |
Price to Book Value Related Metrics
| PS Ratio | 7.056 |
| Price to Free Cash Flow | 371.88 |
| Price | 55.64 |
| Earnings Yield | -1.94% |
| Market Cap | 1.615B |
| Operating PE Ratio | 40.19 |